We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+17.02%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.04B
AUM Growth
+$139M
Cap. Flow
+$41.9M
Cap. Flow %
2.06%
Top 10 Hldgs %
54.88%
Holding
72
New
11
Increased
1
Reduced
5
Closed
4

Top Buys

Rank Stock Value
1
KYMR icon
Kymera Therapeutics
KYMR
+$19.9M
2
QURE icon
uniQure
QURE
+$14.5M
3
NRIX icon
Nurix Therapeutics
NRIX
+$12.8M
4
APGE icon
Apogee Therapeutics
APGE
+$8.58M
5
TIL icon
Instil Bio
TIL
+$8.37M

Top Sells

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$12.7M
2
ALLO icon
Allogene Therapeutics
ALLO
+$8.97M
3
NKTX icon
Nkarta
NKTX
+$8.97M
4
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
+$7.66M
5
PRLD icon
Prelude Therapeutics
PRLD
+$3.98M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
51
Scholar Rock
SRRK
$6.33B
$6.01M 0.29%
+750,000
New +$6.59M
PSTX
52
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$5.72M 0.28%
2,000,000
-2,475,000
-55% -$7.66M
SMMT icon
53
Summit Therapeutics
SMMT
$10.7B
$5.47M 0.27%
+250,000
New +$3.5M
ENGN icon
54
enGene Therapeutics
ENGN
$122M
$4.8M 0.24%
727,900
– –
PRLD icon
55
Prelude Therapeutics
PRLD
$335M
$3.54M 0.17%
1,708,187
-860,100
-33% -$3.98M
BCAX
56
Bicara Therapeutics
BCAX
$1.82B
$3.44M 0.17%
+135,000
New +$3.44M
MRSN
57
DELISTED
Mersana Therapeutics
MRSN
$3.43M 0.17%
+72,680
New +$3.21M
BOLD
58
Boundless Bio
BOLD
$55.7M
$2.47M 0.12%
711,329
– –
BDTX icon
59
Black Diamond Therapeutics
BDTX
$103M
$2.2M 0.11%
506,000
– –
ZNTL icon
60
Zentalis Pharmaceuticals
ZNTL
$364M
$1.66M 0.08%
450,000
– –
TARA icon
61
Protara Therapeutics
TARA
$230M
$1.49M 0.07%
811,627
– –
OBIO icon
62
Orchestra BioMed
OBIO
$220M
$1.22M 0.06%
238,193
– –
ZURA icon
63
Zura Bio
ZURA
$518M
$1.22M 0.06%
+300,000
New +$1.12M
BCAB icon
64
BioAtla
BCAB
$6.56M
$1.21M 0.06%
13,727
– –
MIST icon
65
Milestone Pharmaceuticals
MIST
$148M
$470K 0.02%
309,007
– –
DBVT
66
DBV Technologies
DBVT
$870M
$175K 0.01%
50,000
– –
NUVB.WS
67
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$26.1K ﹤0.01%
266,666
– –
SRZNW icon
68
Surrozen Inc Warrant
SRZNW
$1.33K ﹤0.01%
66,666
– –
ABSI icon
69
Absci
ABSI
$1.4B
– –
-700,000
Closed -$2.16M
ALLO icon
70
Allogene Therapeutics
ALLO
$618M
– –
-3,850,000
Closed -$8.97M
AMLX icon
71
Amylyx Pharmaceuticals
AMLX
$1.97B
– –
-1,500,000
Closed -$2.85M
ATRA icon
72
Atara Biotherapeutics
ATRA
$75.6M
– –
-166,000
Closed -$1.41M
1 2
3

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Boxer Capital held 72 positions worth $2.04B, up 7.3% from $1.9B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Boxer Capital's Q3 2024 filing shows 11 new, 1 increased, 5 reduced and 4 closed positions. Its largest new stake was Kymera Therapeutics: 450,000 shares worth $21.3M. The largest sale was Fate Therapeutics, an estimated $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Boxer Capital's largest Q3 2024 buy was Kymera Therapeutics: 450,000 shares worth $21.3M.
  • Boxer Capital added most to Cullinan Oncology in Q3 2024, an estimated $4.43M increase.
  • Boxer Capital's biggest Q3 2024 reduction was Fate Therapeutics, cutting an estimated $12.7M.
  • Boxer Capital fully exited Allogene Therapeutics in Q3 2024, selling an estimated $8.97M.
  • Boxer Capital's ten largest holdings make up 55% of its $2.04B portfolio in Q3 2024.
  • Boxer Capital opened 11 new positions and closed 4 in Q3 2024.
  • Boxer Capital's portfolio value rose 7.3% quarter-over-quarter to $2.04B.

Based on Boxer Capital's 13F filing for Q3 2024, filed 14 Nov 2024.